TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026
I'm PortAI, I can summarize articles.
TScan Therapeutics announced updated data from the ALLOHA Phase 1 trial for TSC-101 in hematologic malignancies and plans for a pivotal study in 2026. A virtual KOL event will discuss two-year relapse data, a new manufacturing process, and market opportunities. Results will be presented at the 67th ASH Annual Meeting. The original content was published by TScan Therapeutics via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments